Volume Alert - ABBV 65.28 Abbvie Inc. Common Stock $ABBV Hit a high today of 65.52 Closing the day 10:30 at 65.28 -0.22 -0.34% With a day low of 64.96 and a total volume of 1,062,642.
ABBV Recent Posts: http://investorshangout.com/AbbVie-Inc-ABBV-90091/
ABBV Abbvie Inc. Common Stock Recent Headline News
FDA clears Purdue's abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - 36 mins ago
MNK: 86.80 (+0.82), EGLT: 6.54 (+0.30), ZGNX: 1.20 (-0.01), PFE: 30.45 (+0.01), TEVA: 57.08 (-0.17), ABBV: 65.37 (-0.13), ALKS: 55.06 (+0.80), ACUR: 0.52 (-0.01)
Tracking John Paulson's Paulson & Company Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Thu Nov 20, 12:49AM CST
RKT: 55.82 (-0.08), KOG: 10.17 (+0.41), MEAS: 86.00 (+0.01), HHC: 147.81 (+1.89), AET: 86.08 (+0.53), DLPH: 71.04 (-0.06), DLTR: 65.72 (+3.09), AEM: 26.86 (+0.81), AUXL: 33.20 (+0.17), DG: 66.97 (+0.87), ABBV: 65.37 (-0.13), DXM: 8.28 (+0.02), MNK: 86.80 (+0.82), ATHL: 58.40 (unch), NCQ: 0.69 (unch), COV: 97.56 (+0.06), AU: 9.51 (+0.17), MYL: 55.22 (-0.46), IAG: 2.24 (+0.03), FDO: 78.44 (-0.01), MGM: 22.24 (+0.05), GNW: 9.20 (+0.07), HIG: 40.82 (+0.02), NG: 2.90 (+0.10), EQIX: 221.38 (-4.30), HSH: 62.96 (unch), OAS: 26.64 (+0.79), PETM: 78.03 (-0.16), ACT: 258.81 (-7.23), MDT: 71.81 (+0.05), BPOP: 31.83 (-0.17), ENZY: 8.35 (-0.05), FCX: 28.44 (+0.36), GFI: 4.25 (+0.16), CZR: 15.08 (+0.71), CVC: 18.86 (-0.07), CIE: 10.78 (+0.65), CACQ: 10.41 (+0.22), AGN: 209.93 (-2.66), ECA: 18.09 (+0.29), FCH: 10.26 (+0.20), R: 90.82 (+0.27), DTV: 87.12 (-0.10), KMDA: 3.27 (-0.12), ANV: 1.73 (+0.24), MOVE: 20.95 (-0.03), BAC: 16.97 (-0.09), GRFS: 36.63 (+0.25), POST: 36.02 (+0.48), HCA: 67.55 (+0.51), RDN: 16.89 (+0.16), BEE: 12.99 (+0.05), CPWR: 10.27 (+0.11), GLD: 114.57 (+0.89), RLGY: 44.24 (+1.30), MTG: 9.25 (+0.28), HMHC: 20.00 (+0.06), CMCSA: 54.32 (-0.06), CBS: 53.78 (+0.44), BABA: 110.98 (+2.16)
Independent Thinking For Successful Dividend Investing
Dividend Growth Investor - at Seeking Alpha - Wed Nov 19, 8:52PM CST
I enjoy dividend investing, because it is always challenging but it is also very rewarding. I have a set level of basic guidelines such as my entry criteria I apply on the list of dividend champions and achievers, in order to identify companies for...
ABT: 43.62 (+0.19), DLR: 68.36 (-0.19), ABBV: 65.37 (-0.13), FDO: 78.44 (-0.01), O: 45.90 (unch)
Rheumatoid Arthritis Therapeutics Clinical Trials Market by Region, Companies, Trial Status, Phase H2 2014
PRWeb - Wed Nov 19, 7:33PM CST
The clinical trial report, "Rheumatoid Arthritis Global Clinical Trials Review, H2, 2014" provides data on the Rheumatoid Arthritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Rheumatoid Arthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Rheumatoid Arthritis. Complete Report is Available @ http://www.reportsnreports.com/reports/317200...-2014.html .
JNJ: 108.09 (-0.67), PFE: 30.45 (+0.01), MRK: 59.27 (-0.37), AZN: 74.24 (-1.14), ABBV: 65.37 (-0.13), BMY: 58.65 (-0.16)
Gilead Gains on Harvoni's EU Approval for HCV Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 4:57PM CST
Gilead's (GILD) hepatitis C virus drug, Harvoni, gained EU approval for the treatment of adults suffering from chronic hepatitis C genotype 1 and 4 infection.
BIIB: 300.44 (-3.17), GILD: 101.36 (-0.98), MRK: 59.27 (-0.37), ABBV: 65.37 (-0.13)
Why We're Huge Fans Of Gilead
Valuentum - at Seeking Alpha - Wed Nov 19, 3:33PM CST
GILD: 101.36 (-0.98), ABBV: 65.37 (-0.13)
AstraZeneca Targets More than $45B in Revenues in 2023 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 3:20PM CST
AstraZeneca (AZN) provided an update on its growth plans for the future.
AGN: 209.93 (-2.66), AZN: 74.24 (-1.14), ABBV: 65.37 (-0.13)
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 10:23AM CST
Regulatory updates from Gilead (GILD) and Regeneron (REGN) and Geron's (GERN) deal with J&J were the highlights last week in the biotech sector.
GILD: 101.36 (-0.98), GERN: 3.25 (+0.14), CLDX: 20.83 (+2.10), CYTR: 2.56 (-0.07), AMGN: 164.40 (+1.76), ABBV: 65.37 (-0.13), REGN: 409.56 (-5.69)
Tracking George Soros's Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Wed Nov 19, 4:48AM CST
HLF: 39.75 (+1.09), VIPS: 22.71 (+0.27), CNX: 41.45 (+0.68), MON: 119.86 (+0.30), DAL: 44.11 (-0.34), CHTR: 159.33 (+0.70), ESNT: 23.10 (+0.66), CNP: 24.39 (+0.01), INTC: 35.54 (+1.19), GOOG: 534.80 (-2.19), CTXS: 64.80 (+0.18), MSI: 65.88 (-0.06), EEM: 41.16 (-0.04), SPY: 205.44 (+0.22), AAL: 44.52 (+0.42), ABBV: 65.37 (-0.13), GDX: 19.71 (+0.52), MSFT: 48.42 (+0.20), SYK: 89.61 (-0.03), PSX: 77.48 (+1.71), FB: 73.57 (+0.24), HAL: 49.15 (+0.72), PLCM: 13.18 (+0.08), LVLT: 49.17 (+0.08), TEVA: 57.08 (-0.17), AIG: 54.43 (+0.41), IWM: 116.05 (+0.90), DOW: 51.38 (-0.10), LUK: 24.15 (-0.09), VRX: 142.33 (-0.14), LBTYK: 44.91 (-0.28), CLI: 18.99 (unch), CZR: 15.08 (+0.71), CACQ: 10.41 (+0.22), EGN: 68.25 (+1.95), TIBX: 23.72 (+0.02), LBTYA: 46.00 (-0.28), ALLE: 54.15 (+0.15), SEMG: 80.44 (-0.23), AGRO: 9.31 (-0.01), GOOGL: 543.87 (-3.33), NICE: 46.59 (+0.73), AAPL: 116.48 (+1.81), WAG: 67.42 (-0.37), XLE: 87.00 (+0.72), WNR: 41.99 (-0.20), PVA: 8.10 (+0.18), DISH: 72.67 (-1.99), EQT: 95.61 (-0.33), LORL: 73.72 (+0.31), BIDU: 239.36 (-1.06), QQQ: 103.63 (+0.42), GM: 31.96 (-0.19), HUB.B: 108.78 (-0.35), BABA: 110.98 (+2.16)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 258.92 (-7.12), QLTI: 3.94 (-0.05), VRX: 142.33 (-0.14), AGN: 209.93 (-2.66), SHPG: 211.21 (+3.63), AUXL: 33.20 (+0.17), ABBV: 65.37 (-0.13), SNY: 46.99 (-1.10), ABT: 43.62 (+0.19), ENDP: 69.53 (+0.52), AKRX: 37.91 (-0.27), PFE: 30.45 (+0.01), INCY: 71.15 (-0.15), SLXP: 103.16 (-0.47), MYL: 55.22 (-0.46), AMGN: 164.41 (+1.77), LLY: 66.83 (-0.38), GSK: 46.53 (+0.28), BMY: 58.65 (-0.16), ACHN: 13.17 (+0.26), MRK: 59.28 (-0.36), AZN: 74.24 (-1.14), ICPT: 155.88 (-0.05), TEVA: 57.08 (-0.17), NVS: 95.41 (-0.32)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 258.94 (-7.10), QLTI: 3.94 (-0.05), VRX: 142.33 (-0.14), AGN: 209.92 (-2.67), SHPG: 211.21 (+3.63), AUXL: 33.20 (+0.17), ABBV: 65.38 (-0.12), SNY: 46.99 (-1.10), ABT: 43.62 (+0.19), ENDP: 69.53 (+0.52), AKRX: 37.91 (-0.27), PFE: 30.45 (+0.01), INCY: 71.15 (-0.15), SLXP: 103.16 (-0.47), MYL: 55.22 (-0.46), AMGN: 164.41 (+1.77), LLY: 66.83 (-0.38), GSK: 46.53 (+0.28), BMY: 58.65 (-0.16), ACHN: 13.17 (+0.26), MRK: 59.28 (-0.36), AZN: 74.24 (-1.14), ICPT: 155.88 (-0.05), TEVA: 57.08 (-0.17), NVS: 95.41 (-0.32)
Celldex Therapeutics Surges on Positive Rindopepimut Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:05PM CST
Celldex Therapeutics announced encouraging interim update from the phase II ReACT study evaluating the use of rindopepimut.
ACT: 258.94 (-7.10), CLDX: 20.83 (+2.10), ABBV: 65.38 (-0.12)
Roche's (RHHBY) Avastin Label Expansion Approved by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:45PM CST
Roche (RHHBY) announced that the FDA has approved Avastin in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer.
AGN: 209.92 (-2.67), ABBV: 65.38 (-0.12), BMY: 58.65 (-0.16)
Novartis Presents Data on Heart Failure Candidate LCZ696 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:44PM CST
Novartis (NVS) announced new data on pipeline candidate, LCZ696, from the phase III study, PARADIGM-HF.
AGN: 209.92 (-2.67), ABBV: 65.38 (-0.12), BMY: 58.65 (-0.16), NVS: 95.41 (-0.32)
Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST
JNJ: 108.09 (-0.67), GILD: 101.38 (-0.96), MRK: 59.28 (-0.36), AMGN: 164.45 (+1.81), ABBV: 65.38 (-0.12), BMY: 58.65 (-0.16), CELG: 107.38 (+0.40)
Enanta And AbbVie's ABT-450 Likely To Receive FDA Approval
Beacon VP Investments - at Seeking Alpha - Tue Nov 18, 10:13AM CST
ABBV: 65.38 (-0.12), ENTA: 43.95 (+0.05)
Dispelling Some Of The Myths Surrounding Gilead Sciences.
Alexander J. Poulos - Seeking Alpha - Tue Nov 18, 7:22AM CST
Gilead Sciences (NASDAQ: GILD ) has come under fire recently, as many are fretting about the long-term viability of the company's hepatitis C franchise (HCV). The article below will build the case for the superiority of the GILD treatment as opposed...
GILD: 101.37 (-0.97), ABBV: 65.38 (-0.12)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 209.92 (-2.67), MRK: 59.28 (-0.36), ABBV: 65.38 (-0.12), BMY: 58.65 (-0.16)
Will IPOs WhiteWave, Enanta Surpass Buy Points?
at Investor's Business Daily - Mon Nov 17, 5:27PM CST
With the market in a confirmed uptrend, many IPO Leaders are extended beyond their buy points. But a few, including WhiteWave Foods (WWAV) and Enanta Pharmaceuticals (ENTA), are still within striking distance. WhiteWave has been trading near a 37.25...
WWAV: 36.21 (-0.69), ABBV: 65.38 (-0.12), ENTA: 43.95 (+0.05), NVS: 95.41 (-0.32)
Jim Cramer Answers Twitter (TWTR) Questions on Gold, Gilead and More
at The Street - Mon Nov 17, 1:53PM CST
TheStreet's Jim Cramer answers Twitter (TWTR) questions on gold, Gilead (GILD), energy stocks and more.
JNJ: 108.09 (-0.67), GILD: 101.38 (-0.96), GLD: 114.57 (+0.89), ABBV: 65.38 (-0.12), TWTR: 39.81 (+0.10), NVS: 95.41 (-0.32)
ABBV Recent Posts: http://investorshangout.com/AbbVie-Inc-ABBV-90091/
ABBV Abbvie Inc. Common Stock Recent Headline News
FDA clears Purdue's abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - 36 mins ago
MNK: 86.80 (+0.82), EGLT: 6.54 (+0.30), ZGNX: 1.20 (-0.01), PFE: 30.45 (+0.01), TEVA: 57.08 (-0.17), ABBV: 65.37 (-0.13), ALKS: 55.06 (+0.80), ACUR: 0.52 (-0.01)
Tracking John Paulson's Paulson & Company Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Thu Nov 20, 12:49AM CST
RKT: 55.82 (-0.08), KOG: 10.17 (+0.41), MEAS: 86.00 (+0.01), HHC: 147.81 (+1.89), AET: 86.08 (+0.53), DLPH: 71.04 (-0.06), DLTR: 65.72 (+3.09), AEM: 26.86 (+0.81), AUXL: 33.20 (+0.17), DG: 66.97 (+0.87), ABBV: 65.37 (-0.13), DXM: 8.28 (+0.02), MNK: 86.80 (+0.82), ATHL: 58.40 (unch), NCQ: 0.69 (unch), COV: 97.56 (+0.06), AU: 9.51 (+0.17), MYL: 55.22 (-0.46), IAG: 2.24 (+0.03), FDO: 78.44 (-0.01), MGM: 22.24 (+0.05), GNW: 9.20 (+0.07), HIG: 40.82 (+0.02), NG: 2.90 (+0.10), EQIX: 221.38 (-4.30), HSH: 62.96 (unch), OAS: 26.64 (+0.79), PETM: 78.03 (-0.16), ACT: 258.81 (-7.23), MDT: 71.81 (+0.05), BPOP: 31.83 (-0.17), ENZY: 8.35 (-0.05), FCX: 28.44 (+0.36), GFI: 4.25 (+0.16), CZR: 15.08 (+0.71), CVC: 18.86 (-0.07), CIE: 10.78 (+0.65), CACQ: 10.41 (+0.22), AGN: 209.93 (-2.66), ECA: 18.09 (+0.29), FCH: 10.26 (+0.20), R: 90.82 (+0.27), DTV: 87.12 (-0.10), KMDA: 3.27 (-0.12), ANV: 1.73 (+0.24), MOVE: 20.95 (-0.03), BAC: 16.97 (-0.09), GRFS: 36.63 (+0.25), POST: 36.02 (+0.48), HCA: 67.55 (+0.51), RDN: 16.89 (+0.16), BEE: 12.99 (+0.05), CPWR: 10.27 (+0.11), GLD: 114.57 (+0.89), RLGY: 44.24 (+1.30), MTG: 9.25 (+0.28), HMHC: 20.00 (+0.06), CMCSA: 54.32 (-0.06), CBS: 53.78 (+0.44), BABA: 110.98 (+2.16)
Independent Thinking For Successful Dividend Investing
Dividend Growth Investor - at Seeking Alpha - Wed Nov 19, 8:52PM CST
I enjoy dividend investing, because it is always challenging but it is also very rewarding. I have a set level of basic guidelines such as my entry criteria I apply on the list of dividend champions and achievers, in order to identify companies for...
ABT: 43.62 (+0.19), DLR: 68.36 (-0.19), ABBV: 65.37 (-0.13), FDO: 78.44 (-0.01), O: 45.90 (unch)
Rheumatoid Arthritis Therapeutics Clinical Trials Market by Region, Companies, Trial Status, Phase H2 2014
PRWeb - Wed Nov 19, 7:33PM CST
The clinical trial report, "Rheumatoid Arthritis Global Clinical Trials Review, H2, 2014" provides data on the Rheumatoid Arthritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Rheumatoid Arthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Rheumatoid Arthritis. Complete Report is Available @ http://www.reportsnreports.com/reports/317200...-2014.html .
JNJ: 108.09 (-0.67), PFE: 30.45 (+0.01), MRK: 59.27 (-0.37), AZN: 74.24 (-1.14), ABBV: 65.37 (-0.13), BMY: 58.65 (-0.16)
Gilead Gains on Harvoni's EU Approval for HCV Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 4:57PM CST
Gilead's (GILD) hepatitis C virus drug, Harvoni, gained EU approval for the treatment of adults suffering from chronic hepatitis C genotype 1 and 4 infection.
BIIB: 300.44 (-3.17), GILD: 101.36 (-0.98), MRK: 59.27 (-0.37), ABBV: 65.37 (-0.13)
Why We're Huge Fans Of Gilead
Valuentum - at Seeking Alpha - Wed Nov 19, 3:33PM CST
GILD: 101.36 (-0.98), ABBV: 65.37 (-0.13)
AstraZeneca Targets More than $45B in Revenues in 2023 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 3:20PM CST
AstraZeneca (AZN) provided an update on its growth plans for the future.
AGN: 209.93 (-2.66), AZN: 74.24 (-1.14), ABBV: 65.37 (-0.13)
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 10:23AM CST
Regulatory updates from Gilead (GILD) and Regeneron (REGN) and Geron's (GERN) deal with J&J were the highlights last week in the biotech sector.
GILD: 101.36 (-0.98), GERN: 3.25 (+0.14), CLDX: 20.83 (+2.10), CYTR: 2.56 (-0.07), AMGN: 164.40 (+1.76), ABBV: 65.37 (-0.13), REGN: 409.56 (-5.69)
Tracking George Soros's Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Wed Nov 19, 4:48AM CST
HLF: 39.75 (+1.09), VIPS: 22.71 (+0.27), CNX: 41.45 (+0.68), MON: 119.86 (+0.30), DAL: 44.11 (-0.34), CHTR: 159.33 (+0.70), ESNT: 23.10 (+0.66), CNP: 24.39 (+0.01), INTC: 35.54 (+1.19), GOOG: 534.80 (-2.19), CTXS: 64.80 (+0.18), MSI: 65.88 (-0.06), EEM: 41.16 (-0.04), SPY: 205.44 (+0.22), AAL: 44.52 (+0.42), ABBV: 65.37 (-0.13), GDX: 19.71 (+0.52), MSFT: 48.42 (+0.20), SYK: 89.61 (-0.03), PSX: 77.48 (+1.71), FB: 73.57 (+0.24), HAL: 49.15 (+0.72), PLCM: 13.18 (+0.08), LVLT: 49.17 (+0.08), TEVA: 57.08 (-0.17), AIG: 54.43 (+0.41), IWM: 116.05 (+0.90), DOW: 51.38 (-0.10), LUK: 24.15 (-0.09), VRX: 142.33 (-0.14), LBTYK: 44.91 (-0.28), CLI: 18.99 (unch), CZR: 15.08 (+0.71), CACQ: 10.41 (+0.22), EGN: 68.25 (+1.95), TIBX: 23.72 (+0.02), LBTYA: 46.00 (-0.28), ALLE: 54.15 (+0.15), SEMG: 80.44 (-0.23), AGRO: 9.31 (-0.01), GOOGL: 543.87 (-3.33), NICE: 46.59 (+0.73), AAPL: 116.48 (+1.81), WAG: 67.42 (-0.37), XLE: 87.00 (+0.72), WNR: 41.99 (-0.20), PVA: 8.10 (+0.18), DISH: 72.67 (-1.99), EQT: 95.61 (-0.33), LORL: 73.72 (+0.31), BIDU: 239.36 (-1.06), QQQ: 103.63 (+0.42), GM: 31.96 (-0.19), HUB.B: 108.78 (-0.35), BABA: 110.98 (+2.16)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 258.92 (-7.12), QLTI: 3.94 (-0.05), VRX: 142.33 (-0.14), AGN: 209.93 (-2.66), SHPG: 211.21 (+3.63), AUXL: 33.20 (+0.17), ABBV: 65.37 (-0.13), SNY: 46.99 (-1.10), ABT: 43.62 (+0.19), ENDP: 69.53 (+0.52), AKRX: 37.91 (-0.27), PFE: 30.45 (+0.01), INCY: 71.15 (-0.15), SLXP: 103.16 (-0.47), MYL: 55.22 (-0.46), AMGN: 164.41 (+1.77), LLY: 66.83 (-0.38), GSK: 46.53 (+0.28), BMY: 58.65 (-0.16), ACHN: 13.17 (+0.26), MRK: 59.28 (-0.36), AZN: 74.24 (-1.14), ICPT: 155.88 (-0.05), TEVA: 57.08 (-0.17), NVS: 95.41 (-0.32)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 258.94 (-7.10), QLTI: 3.94 (-0.05), VRX: 142.33 (-0.14), AGN: 209.92 (-2.67), SHPG: 211.21 (+3.63), AUXL: 33.20 (+0.17), ABBV: 65.38 (-0.12), SNY: 46.99 (-1.10), ABT: 43.62 (+0.19), ENDP: 69.53 (+0.52), AKRX: 37.91 (-0.27), PFE: 30.45 (+0.01), INCY: 71.15 (-0.15), SLXP: 103.16 (-0.47), MYL: 55.22 (-0.46), AMGN: 164.41 (+1.77), LLY: 66.83 (-0.38), GSK: 46.53 (+0.28), BMY: 58.65 (-0.16), ACHN: 13.17 (+0.26), MRK: 59.28 (-0.36), AZN: 74.24 (-1.14), ICPT: 155.88 (-0.05), TEVA: 57.08 (-0.17), NVS: 95.41 (-0.32)
Celldex Therapeutics Surges on Positive Rindopepimut Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:05PM CST
Celldex Therapeutics announced encouraging interim update from the phase II ReACT study evaluating the use of rindopepimut.
ACT: 258.94 (-7.10), CLDX: 20.83 (+2.10), ABBV: 65.38 (-0.12)
Roche's (RHHBY) Avastin Label Expansion Approved by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:45PM CST
Roche (RHHBY) announced that the FDA has approved Avastin in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer.
AGN: 209.92 (-2.67), ABBV: 65.38 (-0.12), BMY: 58.65 (-0.16)
Novartis Presents Data on Heart Failure Candidate LCZ696 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:44PM CST
Novartis (NVS) announced new data on pipeline candidate, LCZ696, from the phase III study, PARADIGM-HF.
AGN: 209.92 (-2.67), ABBV: 65.38 (-0.12), BMY: 58.65 (-0.16), NVS: 95.41 (-0.32)
Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST
JNJ: 108.09 (-0.67), GILD: 101.38 (-0.96), MRK: 59.28 (-0.36), AMGN: 164.45 (+1.81), ABBV: 65.38 (-0.12), BMY: 58.65 (-0.16), CELG: 107.38 (+0.40)
Enanta And AbbVie's ABT-450 Likely To Receive FDA Approval
Beacon VP Investments - at Seeking Alpha - Tue Nov 18, 10:13AM CST
ABBV: 65.38 (-0.12), ENTA: 43.95 (+0.05)
Dispelling Some Of The Myths Surrounding Gilead Sciences.
Alexander J. Poulos - Seeking Alpha - Tue Nov 18, 7:22AM CST
Gilead Sciences (NASDAQ: GILD ) has come under fire recently, as many are fretting about the long-term viability of the company's hepatitis C franchise (HCV). The article below will build the case for the superiority of the GILD treatment as opposed...
GILD: 101.37 (-0.97), ABBV: 65.38 (-0.12)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 209.92 (-2.67), MRK: 59.28 (-0.36), ABBV: 65.38 (-0.12), BMY: 58.65 (-0.16)
Will IPOs WhiteWave, Enanta Surpass Buy Points?
at Investor's Business Daily - Mon Nov 17, 5:27PM CST
With the market in a confirmed uptrend, many IPO Leaders are extended beyond their buy points. But a few, including WhiteWave Foods (WWAV) and Enanta Pharmaceuticals (ENTA), are still within striking distance. WhiteWave has been trading near a 37.25...
WWAV: 36.21 (-0.69), ABBV: 65.38 (-0.12), ENTA: 43.95 (+0.05), NVS: 95.41 (-0.32)
Jim Cramer Answers Twitter (TWTR) Questions on Gold, Gilead and More
at The Street - Mon Nov 17, 1:53PM CST
TheStreet's Jim Cramer answers Twitter (TWTR) questions on gold, Gilead (GILD), energy stocks and more.
JNJ: 108.09 (-0.67), GILD: 101.38 (-0.96), GLD: 114.57 (+0.89), ABBV: 65.38 (-0.12), TWTR: 39.81 (+0.10), NVS: 95.41 (-0.32)
